Clinical Research Fellow @KCLImmunoMicro•Rheumatology Registrar•@EMEUNET rep to EULAR-PARE•Editorial Board @RheumJnl•#Comorbidities #SocialDeterminantsOfHealth
London, England
Joined May 2019
- Tweets2.4K
- Following1.3K
- Followers1.3K
- Likes10K
Pinned Tweet
Delighted to share our paper on #multimorbidity in #RA emphasising a need for:
-Operationalised definition of MM
-Clearer distinction between MM & #comorbidity in literature
-Greater understanding of MM to encourage holistic care
@RheumJnl @ElenaNikiUK
academic.oup.com/rheumatolog…
Mrinalini Dey retweeted
Generative AI is increasingly being used in rheumatology practice. A new narrative review in Arthritis Care & Research proposes a framework for rheumatology professionals to assess the function of generative AI applications in clinical care.
🔓 Open access → doi.org/10.1002/acr.80195
ALT Generative AI in clinical practice: how should rheumatologists evaluate and monitor emerging tools? Graphical abstract made using BioRender
Mrinalini Dey retweeted
Our August 2026 issue is live!
Including research on sacroiliac joint #bonemarrowoedema, a precision medicine tool in #Sjögrens disease, the role of #healthliteracy in #inflammatoryarthritis, plus much more! thelancet.com/journals/lanrh…
Cover by @emmacreats
Mrinalini Dey retweeted
📢 NEWS ALERT!
EULAR has updated and unified recommendations for the management of polymyalgia rheumatica and large vessel vasculitis, bringing together the latest evidence to support improved diagnosis, treatment, and patient outcomes.
More here 👉 pulse.ly/8wg5sr5edt
Mrinalini Dey retweeted
Proud to share my first first-author publication published today in @Rheumatol_Int . It has been a rewarding project over the past 2 years. Thanks to my amazing sister & co-author @DrMiniDey for her guidance and support. 🤩 📝
doi.org/10.1007/s00296-026-0…
First “Dey & Dey” article combining mine and @MaliniDey6’s interests in RMDs and cancer biology.
Hopefully the first of many more to come!
👯🏻♀️
Mrinalini Dey retweeted
RA-ILD: Screening risk and genetic susceptibility
Two abstracts presented at EULAR 2026 add important insights into identifying patients at risk for RA-ILD and understanding the genetic mechanisms that may underpin disease development.
buff.ly/2VGzyWb
First “Dey & Dey” article combining mine and @MaliniDey6’s interests in RMDs and cancer biology.
Hopefully the first of many more to come!
👯🏻♀️
PARP1 as a novel therapeutic and diagnostic tool in autoimmune rheumatic diseases: a systematic literature review
@DrMiniDey @dr_emrebilgin @ozlemkilic_md
link.springer.com/article/10…
Mrinalini Dey retweeted
Research Article
Perceived and Objective Physical Function in 2 United States Population-Based Cohorts of Adults With Systemic Lupus Erythematosus
📖 jrheum.org/cgi/content/full/…
@UCSFDOM @JYazdanyMD
#Aging #PhysicalFunction #Lupus
Mrinalini Dey retweeted
#EULAR2026 Want to catch up with the latest breakthrough in research on the last day of the conference? Please find our Day 4 Daily Recap led by @RheumNow and joined by my colleagues @synovialjoints @DrMiniDey 😃
youtu.be/WcnV24DUi0E?si=kBPm…
Mrinalini Dey retweeted
DAY 4 Recap: EULAR 2026 Highlights xitter.cf/i/broadcasts/1XxyggMkb…
#EULAR2026 Updated recommendations on the management of PMR &LVV.
A pleasure to have been part of this huge piece of work, covering 3 distinct conditions, and both diagnosis & management principles.
Watch this space for full guideline coming soon!
#EULAR2026
@RheumNow
An important reminder of the psychosocial determinants of outcomes in RA- it is not just about the pharmacological management.
pubmed.ncbi.nlm.nih.gov/3860…
@ElenaNikiUK @RheumNow #EULAR2026
Comorbidities don’t just impact prognosis, remission and treatment in RA- they impact mortality. Comorbidities cannot be treated in a “one size fits all” approach; they should be assessed and managed on an individual basis.
@ElenaNikiUK
@RheumNow #EULAR2026
Overview of the updated RA treatment guideline- early escalation to a biologic following commencement of methotrexate is key to achieving remission.
ard.eular.org/article/S0003-…
@ElenaNikiUK
@RheumNow
#EULAR2026
#EULAR2026
@ElenaNikiUK takes us through the paradigm shift in RA, with an in-depth overview of how far we’ve come in management.
@RheumNow
#OP0159 #EULAR2026
Multimodal study in D2T RA identified altered brain connectivity patterns linked to pain, psychological features & peripheral transcriptomics. Supports neuroimmune component in D2T RA & need for personalised approaches beyond inflammation control. @RheumNow
Mrinalini Dey retweeted
The #EULAR recommendations for the management of Polymyalgia Rheumatica and Large Vessel Vasculitis were presented today at #EULAR2026 at London by the task force lead Dr Chetan Mukhtyar. It was a privilege to represent India on this international task force! I hope these recommendations lead to the better management of patients with PMT, GCA and Takayasu Arteritis. Watch out for the publication of these recommendations in the future!
#OP0156 #EULAR2026 FT839, CART therapy targeting CD19 & CD38, showed potent depletion of pathogenic B cells, plasmablasts/plasma cells & activated T cells, w/o conditioning chemotherapy. Data suggest potentially more accessible CART approach across autoimmune diseases. @RheumNow
#OP0209 #EULAR2026 SPECIFI-RA
Balinatunfib, oral selective TNFR1 inhibitor designed to preserve TNFR2 signalling in RA. Phase 2b trial missed primary ACR20 endpoint, but 200mg QD arm showed signals for higher ACR50, ACR70 and DAS28 low disease activity & reduced IL-6. @RheumNow
#OP0208 #EULAR2026: phase 3 COURAGE-RA trial showed strong efficacy for selective JAK1 inhibitor zemprocitinib in D2T RA after bDMARD failure. Responses were rapid (from week 2), sustained through week 24 and achieved with a reassuring safety profile. @RheumNow
#OP0207 #EULAR2026: SUPERFIBRES trial suggests dietary fibre supplementation may enhance MTX response in RA. Inulin improved EULAR responses and Th17/Treg balance over 30 days, with strongest effects seen in MTX-treated patients. Fascinating microbiome-linked signal. @RheumNow
